ES2097150T3 - Inhibidores de la agregacion de las plaquetas. - Google Patents

Inhibidores de la agregacion de las plaquetas.

Info

Publication number
ES2097150T3
ES2097150T3 ES90911002T ES90911002T ES2097150T3 ES 2097150 T3 ES2097150 T3 ES 2097150T3 ES 90911002 T ES90911002 T ES 90911002T ES 90911002 T ES90911002 T ES 90911002T ES 2097150 T3 ES2097150 T3 ES 2097150T3
Authority
ES
Spain
Prior art keywords
alkyl
pais
independently
assay
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90911002T
Other languages
English (en)
Other versions
ES2097150T5 (es
Inventor
Robert M Scarborough
David Lawrence Wolf
Israel F Charo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
Original Assignee
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27408820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2097150(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by COR Therapeutics Inc filed Critical COR Therapeutics Inc
Publication of ES2097150T3 publication Critical patent/ES2097150T3/es
Application granted granted Critical
Publication of ES2097150T5 publication Critical patent/ES2097150T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control And Other Processes For Unpacking Of Materials (AREA)
  • External Artificial Organs (AREA)
  • Materials For Medical Uses (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

SE DESCRIBE UNA PRUEBA PARA FILTRAR VENENO DE SERPIENTE POR LA PRESENCIA O AUSENCIA DE INHIBIDORES DE ASOCIACION DE PLAQUETAS (PAIS) BASADA EN UN AGLUTINADOR RECEPTOR ESPECIFICO. UTILIZANDO ESTA PRUEBA, SE LOGRO LA IDENTIFICACION Y CARACTERIZACION DEL PAIS EN UNA GAMA AMPLIA DE MUESTRAS DE VENENO DE SERPIENTE. SE DESCRIBE Y CARACTERIZA EL PAIS AISLADO Y PURIFICADO DE VARIOS DE ESTOS VENENOS ACTIVOS DE SERPIENTE. ADEMAS, EL PAIS SIN LA SECUENCIA DE ADHESION ARG-GLI-ASP(RGD) PERO QUE CONTIENE K* -(G/SAR)-D DONDE K* ES UN RESIDUO LISIL MODIFICADO DE LA FORMULA R1/2 N(CH SUB 2) SUB 4CHNHCO1 ES INDEPENDIENTEMENTE H, ALKIL (1-6C) O AL MENOS UN R ELEVADO 1 ES R (AL CUADRADO) -C=NR ELEVADO 3 DONDE R (AL CUADRADO) ES H, ALKIL (1-6C), FENIL O BENZIL, O R (AL CUADRADO) -C=NR ELEVADO 3 ES UN RADICAL SELECCIONADO DEL GRUPO QUE CONSTA DE (A), (B), (C) Y (D) DONDE M ES UN ENTERO DE 2-3, Y CADA R ELEVADO 5 ES INDEPENDIENTEMENTE H O ALKIL (1-6C); Y DONDE UNO O DOS (CH SUB 2) PUEDEN SER SUSTITUIDOS POR O O SSIEMPRE QUE DICHA O O S NO SEAN ADYACENTES A ESTOS ATOMOS, SE PREPARAN Y MUESTRAN PARA INHIBIR ESPECIFICAMENTE LA UNION DEL FIBRINOGENO O EL FACTOR DE VON WILLEBRAND AL GP IIB-IIIA.
ES90911002T 1989-06-16 1990-06-15 Inhibidores de agregacion plaquetaria. Expired - Lifetime ES2097150T5 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US36750989A 1989-06-16 1989-06-16
US367509 1989-06-16
US41802889A 1989-10-06 1989-10-06
US418028 1989-10-06
US07/483,229 US5318899A (en) 1989-06-16 1990-02-20 Platelet aggregation inhibitors
US483229 1990-02-20

Publications (2)

Publication Number Publication Date
ES2097150T3 true ES2097150T3 (es) 1997-04-01
ES2097150T5 ES2097150T5 (es) 2006-06-16

Family

ID=27408820

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90911002T Expired - Lifetime ES2097150T5 (es) 1989-06-16 1990-06-15 Inhibidores de agregacion plaquetaria.

Country Status (16)

Country Link
US (4) US5318899A (es)
EP (2) EP0477295B2 (es)
JP (1) JP3281370B2 (es)
KR (1) KR0180918B1 (es)
AT (1) ATE146969T1 (es)
CA (2) CA2059124C (es)
DE (2) DE69029579T3 (es)
DK (1) DK0477295T4 (es)
ES (1) ES2097150T5 (es)
FI (1) FI104364B (es)
HU (1) HU216318B (es)
LU (1) LU90488I2 (es)
NL (1) NL990043I2 (es)
NO (3) NO304267B1 (es)
RU (1) RU2156468C2 (es)
WO (1) WO1990015620A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU639409B2 (en) * 1987-12-10 1993-07-29 La Jolla Cancer Research Foundation Conformationally stabilized cell adhesion peptides
US5827821A (en) * 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5780595A (en) * 1989-06-16 1998-07-14 Cor Therapeutics, Inc. Platelet aggregation inhibitors
AU6470590A (en) 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5612311A (en) * 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
AU660926B2 (en) * 1990-04-06 1995-07-13 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5648330A (en) * 1990-04-06 1997-07-15 La Jolla Cancer Research Foundation Method and composition for treating vascular graft occlusion
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
JPH06502407A (ja) * 1990-11-02 1994-03-17 ジェネンテク，インコーポレイテッド 血小板凝集阻害剤
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
AU666853B2 (en) * 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5674865A (en) * 1991-10-18 1997-10-07 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa
US5227490A (en) * 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4212304A1 (de) * 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
KR100297184B1 (ko) * 1992-06-04 2001-10-22 슈테펜엘.네스비트 항혈소판제로서의입체배좌적으로억제된펩타이드동족체및이를포함하는약제학적조성물
IL106197A (en) * 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
AU692439B2 (en) * 1993-03-29 1998-06-11 Zeneca Limited Heterocyclic compounds as platelet aggregation inhibitors
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
ATE202345T1 (de) * 1993-03-29 2001-07-15 Astrazeneca Ab Heterozyklische derivate als plätchenaggregationsinhibitoren
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
ATE195949T1 (de) * 1993-06-18 2000-09-15 Jolla Cancer Res Found Verfahren und zusammensetzungen zur behandlung der thrombose
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds
EP0835135A2 (en) * 1995-06-07 1998-04-15 Centocor, Inc. Platelet-specific chimeric immunoglobulin and methods of use therefor
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
AU1749497A (en) * 1996-01-16 1997-08-11 Rensselaer Polytechnic Institute Peptides for altering osteoblast adhesion
JP2001500875A (ja) * 1996-09-18 2001-01-23 メルク エンド カンパニー インコーポレーテッド 心臓血管系疾患関連の危険性を減らす併用治療法
CA2271684A1 (en) * 1996-11-21 1998-05-28 Merck & Co., Inc. Detection of antagonist-dependent gpiib/iiia receptor antibodies
FR2764389B1 (fr) * 1997-06-06 1999-08-06 Stago Diagnostica Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee
US6177282B1 (en) * 1997-08-12 2001-01-23 Mcintyre John A. Antigens embedded in thermoplastic
WO1999013898A1 (en) * 1997-08-15 1999-03-25 Stefan Niewiarowski EC-3, AN INHIBITOR OF α4β1 AND α4β7 INTEGRINS
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
US6210904B1 (en) 1997-10-14 2001-04-03 Merck & Co., Inc. Anticoagulant test
US6063584A (en) * 1997-11-21 2000-05-16 Merck & Co., Inc. Anticoagulant test
US6087332A (en) * 1997-12-23 2000-07-11 Galler; Lawrence Isaac Streptokinase derivatives with high affinity for activated platelets and methods of their production and use in thrombolytic therapy
CA2320900C (en) 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
WO2002022571A2 (en) * 2000-09-11 2002-03-21 Temple University-Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting alpha-1 beta-1 integrins
DE60233520D1 (de) * 2001-11-05 2009-10-08 Irm Llc Markierungsreagens und anwendungsverfahren
EP1504022B1 (en) * 2002-05-03 2006-10-11 Avecia Limited Process for the synthesis of peptide amides by side-chain attachment to a solid phase
RU2524129C2 (ru) * 2003-01-10 2014-07-27 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
WO2005044978A2 (en) * 2003-07-15 2005-05-19 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
US7723474B2 (en) * 2003-10-21 2010-05-25 The Regents Of The University Of California Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
ES2369872T3 (es) * 2004-04-08 2011-12-07 Millennium Pharmaceuticals, Inc. Procesos para la preparación de eptifibatide y los compuestos intermedios pertinentes.
ATE451384T1 (de) * 2004-06-14 2009-12-15 Usv Ltd Verfahren zur herstellung von peptiden
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
JP2008512098A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
EP1906990B1 (en) * 2005-07-05 2013-12-11 Baker Medical Research Institute Anticoagulation agent
WO2008020743A2 (fr) * 2006-08-16 2008-02-21 Wisdom Asset Company Procédé permettant d'extraire un inhibiteur de l'agrégation plaquettaire du venin d'agkistrodon blomhoffii ussuriensis
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
MX342120B (es) 2010-07-09 2016-09-14 William Owen Wilkison Combinación de sistema de liberación prolongada/inmediata para productos farmacéuticos de vida media corta como el remogliflozin.
RU2444731C1 (ru) * 2010-10-06 2012-03-10 Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) Способ выравнивания хроматограмм пептидных смесей
EP2882792A4 (en) 2012-08-09 2016-04-13 Valspar Sourcing Inc POLYCARBONATE
CN104583347B (zh) 2012-08-09 2016-11-16 威士伯采购公司 稳定剂和其涂料组合物
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN108137653B (zh) 2015-08-05 2021-07-13 陕西麦科奥特科技有限公司 有抗凝血和抗血小板活性的多靶点化合物及制法和用途
CN111601816B (zh) * 2017-08-09 2023-12-22 黄德富 去整合蛋白变异体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4661111A (en) * 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
US4614517A (en) * 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4661471A (en) * 1984-04-10 1987-04-28 New England Deaconess Hospital Method of inhibiting and inducing human platelet aggregation
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
DE3716513A1 (de) * 1987-05-16 1988-11-24 Basf Ag Proteine mit tnf-wirkung
FR2617170B1 (fr) * 1987-06-25 1989-12-22 Inst Nat Sante Rech Med Nouveaux derives peptidiques et leur application notamment en therapeutique
IT1222437B (it) * 1987-08-04 1990-09-05 Ellem Ind Farmaceutica Tripeptidi utili come immunostimolanti e nella prevenzione delle metastasi e relativo procedimento di preparazione
FR2622587B1 (fr) * 1987-10-30 1990-12-21 Inst Vaisseaux Sang Peptide lysyl-arginyl-aspartyl-serine et ses applications en tant que medicament, notamment antithrombotique
DE3886175T2 (de) * 1987-11-18 1994-04-07 Univ Temple Trigramin, ein Polypeptid, das die Aggregation der Blutplättchen hemmt.
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
AU3040589A (en) * 1988-02-22 1989-09-06 Upjohn Company, The Homoarginine-based peptides as platelet aggregation inhibitors
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
US5182260A (en) * 1989-01-27 1993-01-26 Biogen, Inc. Dna sequences encoding snake venom inhibitors of platelet activation processes for producing those inhibitors and compositions using them
EP0382451A3 (en) * 1989-02-07 1991-05-29 Merck & Co. Inc. Viper venom polypeptides and variants
AU5939890A (en) * 1989-06-07 1991-01-07 Genentech Inc. Platelet aggregation inhibitors and related molecules
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors

Also Published As

Publication number Publication date
DE19975072I1 (de) 2000-03-09
AU636159B2 (en) 1993-04-22
US5318899A (en) 1994-06-07
LU90488I2 (fr) 2000-02-15
CA2059124A1 (en) 1990-12-17
US5958732A (en) 1999-09-28
KR920702627A (ko) 1992-10-06
NO982249L (no) 1992-01-31
NL990043I2 (nl) 2000-04-03
JPH05500750A (ja) 1993-02-18
EP0751219A1 (en) 1997-01-02
RU2156468C2 (ru) 2000-09-20
AU6036990A (en) 1991-01-08
CA2388770A1 (en) 1990-12-27
FI104364B (fi) 2000-01-14
DE69029579T3 (de) 2006-06-22
DE19975072I2 (de) 2011-01-20
NO914962D0 (no) 1991-12-16
EP0477295A1 (en) 1992-04-01
US5496724A (en) 1996-03-05
NO914962L (no) 1992-01-31
DE69029579T2 (de) 1997-07-24
HU905490D0 (en) 1992-03-30
EP0477295B1 (en) 1997-01-02
CA2059124C (en) 2002-08-20
DE69029579D1 (de) 1997-02-13
NO982249D0 (no) 1998-05-15
NL990043I1 (nl) 2000-02-01
US5736339A (en) 1998-04-07
ES2097150T5 (es) 2006-06-16
KR0180918B1 (ko) 1999-04-01
ATE146969T1 (de) 1997-01-15
EP0477295A4 (en) 1992-10-07
HUT59835A (en) 1992-07-28
NO304267B1 (no) 1998-11-23
DK0477295T4 (da) 2005-12-12
FI915919A0 (fi) 1991-12-16
HU216318B (hu) 1999-06-28
EP0477295B2 (en) 2005-11-16
NO2000008I2 (no) 2006-01-16
WO1990015620A1 (en) 1990-12-27
JP3281370B2 (ja) 2002-05-13
DK0477295T3 (da) 1997-07-07
NO312965B1 (no) 2002-07-22

Similar Documents

Publication Publication Date Title
ES2097150T3 (es) Inhibidores de la agregacion de las plaquetas.
CA2158268A1 (en) N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
AU581000B2 (en) Preparation of 6-oxygenated-1,3,4,5-tetrahydrobenz``cd`` indol-4-amines and indole-4-one intermediates therefor
AU1634288A (en) Cyclic anticoagulant peptides
AU1634388A (en) Cyclic anticoagulant peptides
FI870176A (fi) Nya foereningar och deras framstaellningsfoerfaranden.
SE8700366L (sv) Medel vid lungfibros

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 477295

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: EPTIFIBATIDE (INTEGRILIN)

Spc suppl protection certif: C9900045

Filing date: 19991224

SPCG Supplementary protection certificate granted

Free format text: EPTIFIBATIDE (INTEGRILIN)

Spc suppl protection certif: C9900045

Filing date: 19991224

Expiry date: 20140701

Effective date: 20030814